Cytek Biosciences Inc (CTKB)
Solvency ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.26 | 1.25 | 1.24 | 1.24 | 1.22 | 1.20 | 1.20 | 1.19 |
The solvency ratios of Cytek Biosciences Inc indicate a consistently low level of debt relative to its assets, capital, and equity over the past few quarters. The debt-to-assets, debt-to-capital, and debt-to-equity ratios have all been calculated at 0.00, suggesting that the company has not relied heavily on debt financing for its operations.
However, the financial leverage ratio has shown a slight upward trend in recent quarters, increasing from 1.13 in Q1 2022 to 1.26 in Q4 2023. This indicates that the company's reliance on debt has slightly increased, leading to a higher level of financial leverage. While the financial leverage ratio is still within a reasonable range, investors and stakeholders should monitor this trend to ensure that the company's capital structure remains sustainable and balanced.
Coverage ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|
| Interest coverage | -10.19 | -6.84 | -3.00 | -0.69 | 1.49 | -0.01 | -0.01 | 2.27 |
Interest coverage ratio is a financial metric used to evaluate a company's ability to pay its interest expenses on outstanding debt. It is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expenses. A higher interest coverage ratio indicates a better ability to meet interest obligations.
Based on the data provided for Cytek Biosciences Inc, the interest coverage ratio has been consistently below 1 in recent quarters, indicating that the company is not generating enough earnings to cover its interest expenses. The negative values in some quarters suggest that the company's EBIT is insufficient to cover its interest charges.
The downward trend in the interest coverage ratio from -10.19 in December 2023 to -0.01 in September 2022 indicates a deteriorating ability of Cytek Biosciences Inc to meet its interest obligations. The company's ability to service its debt and maintain financial stability may be a cause for concern based on these ratios.
It is essential for investors and stakeholders to closely monitor Cytek Biosciences Inc's interest coverage ratio to assess the company's financial health and risk of default on its debt obligations. The negative values suggest that the company may be facing financial challenges that could impact its long-term viability.